AmblyoFix for one-eye (unilateral) amblyopia in children 7–12 years
Official title: Prospective Clinical Trial Evaluating AmblyoFix for the Treatment of Unilateral Amblyopia in Children
Run by Eyesight Electronics · NCT07323953 · Data updated 2026-11-12
This will test whether AmblyoFix, an at-home binocular digital therapy, can improve the weaker eye's vision in children aged 7–12 with unilateral amblyopia compared with past patching treatment.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 7 Years to 12 Years |
| Sex | All |
| Enrollment | 33 (estimated) |
| Sponsor | Eyesight Electronics Industry-sponsored |
| Locations | 1 site (Cairo) |
| Status | Recruiting |
| Started | March 16, 2026 |
| Main results expected | February 25, 2027 |
| Study ends | March 16, 2027 |
| Registry record updated | September 23, 2026 |
| Trial ID | NCT07323953 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Children aged 7–12 with unilateral amblyopia, amblyopic-eye BCVA between 0.3 and 1.3 logMAR, an interocular difference of ≥0.2 logMAR, stable refractive correction, and access to a laptop with internet are the ideal candidates.
✕Probably not a fit
Children with prior amblyopia treatment beyond refractive adaptation, severe ocular pathology or high myopia, significant cognitive/developmental delay, a history of light-induced seizures, or no suitable home computer/internet are unlikely to benefit or qualify.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective, single-arm, non-inferiority trial testing AmblyoFix binocular digital therapy delivered at home and comparing outcomes to a retrospective cohort previously treated with patching. Thirty-three children aged 7–12 with unilateral amblyopia and specified visual acuity and refractive stability will be enrolled to allow for at least 28 completers at Week 24. The primary outcome is change in amblyopic-eye best-corrected visual acuity (logMAR) from baseline to Week 24 measured under standardized Snellen or ETDRS protocols by certified, masked outcome assessors. Therapy adherence, safety, and vision outcomes will be monitored with digital logging and clinic visits.
Why it matters
Potential benefit: If successful, AmblyoFix could provide an effective at-home alternative to patching that improves vision in the amblyopic eye for older children.
How similar studies have gone: Previous trials of binocular digital therapies for amblyopia have shown mixed but promising results—some matched patching while others did not—so the approach has partial supporting evidence but is not yet definitive.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 7-12 years. * Unilateral amblyopia secondary to anisometropia and/or mild strabismus. * BCVA in amblyopic eye between 20/40-20/400 (0.3-1.3 logMAR); fellow eye ≥20/32 (≤0.2 logMAR). * Interocular difference ≥2 lines (≥0.2 logMAR). * Stable refractive correction for ≥16 weeks or \<0.1 logMAR change across two visits ≥8 weeks apart. * Cycloplegic refraction within 7 months meeting anisometropia criteria (e.g., hyperopia ≥+2.50 D). * Access to a suitable home environment (laptop and internet). * Parent/guardian consent and child assent (7+ year olds). Exclusion Criteria: * Atropine use within 2 weeks before starting treatment * Prior amblyopia treatment beyond refractive adaptation. * Myopia \>-6.00 D SE, previous ocular surgery, or other ocular pathology. * Severe cognitive/developmental delay impeding compliance. * History of light-induced seizures. * Inability/unwillingness to comply with digital monitoring. * Any condition compromising safety or trial integrity.
Where it's running
-
Watany Research and Development Center, Watany Eye Hospital
Cairo, Egypt Recruiting
Study contacts
- Study coordinator: Dr. Heba Fuoad, MD, PhD Ophthalmology
- Email: hebamfouad@watanyeyehospitals.com
- Phone: +2012260616112
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Psilocybin-assisted therapy to help adults with amblyopia see more clearly
This study tests whether a single or small doses of psilocybin can boost the effectiveness of amblyopia treatment in adults.
-
Augmented Reality Binocular Therapy for Adult Amblyopia
This trial tests a home-based augmented reality binocular therapy to see if it improves vision in adults 18–40 with anisometropic amblyopia, compared with placebo training.
-
Gabor-based visual training for adults with amblyopia
This study tests a computer-based Gabor training program to see if it can improve vision in adults aged 18–39 with amblyopia due to anisometropia or strabismus.
-
Noninvasive brain stimulation plus augmented reality vision therapy for anisometropic amblyopia in adults
This trial tests whether adding HD-tDCS to AR-based dichoptic therapy can improve vision in adults with anisometropic amblyopia.
-
tDCS for paediatric amblyopia
This study tests whether non-invasive brain stimulation (tDCS) can improve vision for children aged 4–14 with amblyopia who didn’t get enough help from patching.
-
Gamified visual training with occlusion for kids with anisometropic amblyopia
This trial tests two kid-friendly digital games plus patching to see if they improve vision and motivation in children aged 4–7 with anisometropic amblyopia compared with patching alone.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.